“Standing by” for Bystander Effects: Dual-Isotope Imaging of Antibody–Drug Conjugate and Payload Distribution

> See the associated article on page [1461][1]. Antibody–drug conjugates (ADCs) are a promising class of therapeutics for the molecular targeting of cancer. There is a significant pharmaceutical investment in this area, with more than 70 ADCs in various stages of clinical trials and 4 clinical